3.92

4.16% -0.17

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $3.92, with a volume of 1.41M. It is down -4.16% in the last 24 hours and down -15.88% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$4.09

Open:

$4.16

24h Volume:

1.41M

Relative Volume:

0.61

Market Cap:

$656.14M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-1.40

EPS:

-2.8

Net Cash Flow:

$-304.44M

1W Performance:

-2.00%

1M Performance:

-15.88%

6M Performance:

-47.17%

1Y Performance:

-62.60%

1-Day Range:

$3.92

$4.24

1-Week Range:

$3.85

$4.24

52-Week Range:

$3.50

$11.02

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

617-370-8837

Address

399 BINNEY STREET, CAMBRIDGE

Employee

294

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	3.92	656.14M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

Feb 20, 2025

Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Feb 20, 2025

Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 20, 2025

Feb 19, 2025

The Potential Rise in the Price of Relay Therapeutics Inc (RLAY) following insiders activity - Knox Daily

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

Feb 19, 2025

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian

Feb 19, 2025

Feb 16, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 Shares - MarketBeat

Feb 14, 2025

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of Stock - MarketBeat

Feb 14, 2025

Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock By Investing.com - Investing.com Australia

Feb 14, 2025

Relay Therapeutics: A Precision Oncology Play Worth The Risk - Seeking Alpha

Feb 14, 2025

Feb 13, 2025

Q2 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat

Feb 13, 2025

Feb 11, 2025

Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down – Should You Sell? - Defense World

Feb 11, 2025

Q2 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Feb 10, 2025

Quarterly Metrics: Quick and Current Ratios for Relay Therapeutics Inc (RLAY) - The Dwinnex

Feb 10, 2025

Feb 08, 2025

Brokers Issue Forecasts for RLAY Q1 Earnings - Defense World

Feb 08, 2025

Feb 07, 2025

RLAY’s Market Whiplash: 9.47% YTD Rise, -1.31% Plunge in 30 Days - The InvestChronicle

Feb 07, 2025

Analysts Set Expectations for RLAY Q1 Earnings - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News

Feb 06, 2025

Feb 05, 2025

BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com

Feb 05, 2025

Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily

Feb 05, 2025

SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Feb 05, 2025

Feb 04, 2025

How should investors view Relay Therapeutics Inc (RLAY)? - US Post News

Feb 04, 2025

Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat

Feb 04, 2025

Feb 03, 2025

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat

Feb 03, 2025

Jan 31, 2025

Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com

Jan 31, 2025

Jan 30, 2025